Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...